Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Four year data for Wegovy (semaglutide) in obesity presented at ECO meeting and published in Nature – Novo Nordisk

Written by | 18 May 2024 | Nutrition

At the European Congress on Obesity in Venice, investigators unveiled results from an analysis published in Nature Medicine evaluating Wegovy’s weight loss benefits over four years. With this new four-year data in hand, Novo Nordisk can make a case for its popular obesity med Wegovy to be used as a long-term treatment.

In more than 17,000 non-diabetic overweight and obese patients who suffered from preexisting heart disease, patients lost an average of nearly 10% of their total body weight after 65 weeks on Wegovy, the investigators said. Patients sustained the results until the end of four years when their average weight loss came to 10.2%..

See- -Published: 13 May 2024.”Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial”; Donna H. Ryan, Ildiko Lingvay, John Deanfield, Steven E. Kahn, Eric Barros, Bartolome Burguera, Helen M. Colhoun, Cintia Cercato, Dror Dicker, Deborah B. Horn, G. Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A. Michael Lincoff, Sebastian M. Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P. van Beek, John P. H. Wilding & Robert F. Kushner Nature Medicine (2024). Nat Med (2024). https://doi.org/10.1038/s41591-024-02996-7.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.